New research has developed a nanoparticle formulation that can knock down a key chlamydia binding protein and simultaneously induce autophagy – showing promise against this infection.
A first for clinical trials in the US as researchers from the University of California San Diego School of Medicine get US FDA approval to use intravenously-administered bacteriophage therapy in hopes of combatting resistant bacteria.
New research has identified a link between the use of non-steroidal anti-inflammatory drugs – commonly used as pain relief – and more severe C. difficile infections in mouse models.
Researchers have successfully used monoclonal antibodies to protect animal models from Candida infections for the first time, demonstrating their potential for treating this fungal disease.
Want to discover the best research that’s occurred this year? Editor, Martha Powell, highlights the best of 2018’s infectious diseases research in an A–Z.
More focus should be put on determining if pathogens are resistant or resilient to antibiotics, according to a new study. This distinction could allow for improved, personalized treatment and help to preserve current antibiotics.
A new trial has begun in the Democratic Republic of Congo, aiming to collect robust data on the safety and efficacy of investigational Ebola therapeutics.
By carefully considering the characteristics of certain old and new antibiotics, it may be possible to overcome many bacterial resistance mechanisms, including when more than one is present.
A Phase II, muti-center, randomized, open-label trial has reported that a novel oral antibiotic, zoliflodacin, is effective in the treatment of uncomplicated urogenital gonorrhea.
New data analysis of three clinical trials has suggested that a precision medicine approach could allow some pulmonary TB patients to have significantly shorter treatment periods.